

# **Drug Discovery Collaborations between Academia and the Pharmaceutical Industry: Cultural factors, intellectual property considerations, case studies, and future trends**

## **Table of Contents**

Drug Discovery Collaborations between Academia and the Pharmaceutical Industry: Cultural factors, intellectual property considerations, case studies, and future trends	
Executive summary	10
Background to collaborative research agreements	10
Critical issues for effective collaborations	11
Management of intellectual property rights	11
Case studies	12
The future of collaborations, licensing, and alliances	14
Chapter 1 Background to collaborative research agreements	16
Summary	16
Innovation and innovation models	17
The closed innovation model	17
The open innovation model	18
Consequences of the open innovation model	20
Intellectual property (IP) protection and open innovation	22
Types of collaborations	24
Sponsored research projects (SPR) contract research	24
Industry mentors for postdoctoral fellows	25
Gifts from companies for unrestricted research support	26
Research centres, industry affiliated programs, or consortia	26
Use of university laboratories, facilities, and centres by company researchers	27
Technological licensing and start-up venture creation	28
Advantages of collaborations between academia and industry	29
Advantages for academia	29
Advantages for the pharmaceutical industry	30
Disadvantages of collaborations between academia and industry	31
Disadvantages for academia	31
Practical difficulties in negotiating and managing a collaboration	31
Deleterious effects on faculty and students	32
Affect on the university reputation and financial challenges	32
Disadvantages for the pharmaceutical industry	33
Commercial interests are a low priority amongst academics	33
Discord regarding intellectual property rights	33
Types of collaboration agreements	34
One-to-one research collaborative agreements	36
Model consortium agreements	37
Identification of suitable collaborators and research partners	38
Strategic fit	39
Impact on internal strengths and weaknesses	39
Impact on strategic direction	40
Critical factors for successful collaboration resource planning	40
Clear support from senior management	40
Dedicated project management for each collaboration team	41
Complimentary strategy for both entities involved in the collaboration	41
Commitment to time and financial resources	41
Commitment to a supportive environment that fosters innovation	41
Assimilation of new knowledge by the sponsoring pharmaceutical company	42
Formulation of a well-defined collaboration agreement	42
Understanding the drafting of contractual terms and conditions	42
Definitions of the agreement	42
Collaboration agreement outline	43
Negotiating the terms and conditions of an agreement	48
Academic institution considerations	48

Pharmaceutical and biopharmaceutical industry considerations 48  
License agreements 48  
Upfront payments or signing fees 51  
Annual or other periodic fees 51  
Milestone payments 52  
Duration and termination 53  
Chapter 2 Critical issues for effective collaborations 56  
Summary 56  
Introduction 57  
Cultural, change management, and goal alignment challenges 57  
Organizational culture 57  
The culture of academia 59  
Pharmaceutical industry corporate culture 60  
Corporate management and research collaborations 62  
Management of open innovation and open science disclosure procedures 64  
Lack of transparency between collaborating partners 65  
Mismatch in time scales between academic study and commercial drive for results 65  
Managing conflict and bridging cultural gaps between collaborating partners 65  
Difference in research questions addressed by academia and industry 66  
Effectiveness and efficiency of knowledge management and knowledge transfer 66  
Institutional incentives and integration of research and educational missions 66  
University reward and incentive structures 66  
Potential misuse of student time and conflicts of interest 67  
Payment of indirect costs incurred by the university 68  
Goal alignment challenges in research collaborations 69  
Challenges associated with technology and knowledge transfer 70  
Challenges associated with the knowledge transfer process 70  
Challenges associated with the technology transfer process 73  
Chapter 3 Management of intellectual property rights 78  
Summary 78  
Introduction 79  
Intellectual property rights and national policy considerations 80  
WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) 80  
The Bayh-Dole Act in the US 82  
The Cooperative Research and Technology Enhancement (CREATE) Act 83  
European position on patents and intellectual property protection 84  
Intellectual property protection issues in Brazil 85  
Russian legislation to strengthen regulation of pharmaceutical IP 86  
Latest regulatory and legislative changes in India 87  
Patent laws and WTO TRIPS in China 88  
R&D collaborations and the uncertainty of intellectual property rights 91  
The duration of patent examinations 91  
Economic and strategic uncertainty for the industry 94  
Uncertainties over publication of proprietary knowledge by academics 96  
Uncertainties over disclosure of unprotected information 96  
Conducting R&D in countries with weak IPR protection 97  
Negotiating and bargaining associated with IPR 98  
Protection of trade secrets 98  
Protection of patentable IP 101  
Chapter 4 Case studies 106  
Summary 106  
AstraZeneca and the University of Virginia 107  
Review of the collaboration by AstraZeneca 109  
Management of IP and entrepreneurial activities at UVa 109  
AstraZeneca optimizes collaboration through interoperable technologies 110  
Roche and the Translational Medicine Research Hub in Singapore 110  
Management of IP and entrepreneurial activities at A\*STAR 112  
Industry collaboration with the University of Dundee and the Medical Research Council (MRC) 113  
Management of IP and entrepreneurial activities at DSTT 114  
Partnership of Sanofi-Aventis with the French Life Sciences and

Healthcare Alliance (AVIESAN)	115
Collaborative alliance between GlaxoSmithKline and the Harvard Stem Cell Institute (HSCI)	115
Other GSK collaborations	116
Problematic collaborations	118
The Scripps Research Institute and Novartis	118
The Scripps Research Institute (TSRI)	118
Novartis AG	119
Collaboration Agreement between TSRI and Novartis	119
The Scripps Research Institute and Pfizer	121
The University of California Berkeley (UCB) and Novartis Agricultural Discovery Institute, Inc (NADII)	121
Controversial aspects	122
Conclusion	124
Chapter 5 The future of collaborations, licensing, and alliances	128
Summary	128
Introduction	129
Changing paradigms in traditional universities	130
The evolution of the corporate university	130
The emergence and evolution of the entrepreneurial university	132
Synergy between ivory tower academics and entrepreneurial scientists	135
The emergence and growth of research clusters and incubator hubs	138
Institutional changes to European university practices	140
Science parks	142
Incubator or enterprise hub models	144
Virtual incubators	145
The Triple Helix model of university–industry–government	147
Appendix	149
Methodology statement	149
Primary data and information gathering	149
Secondary data and information gathering	150
Glossary of abbreviations and acronyms	151
Index	160

## List of Figures

Figure 1.1: The current paradigm: a closed innovation system	18
Figure 1.2: An open innovation system	19
Figure 1.3: Schematic model illustrating knowledge spillover	21
Figure 2.4: The traditional management process	63
Figure 2.5: The university/company knowledge transfer process	73
Figure 2.6: The technology transfer process	74
Figure 3.7: Average duration of US patent applications pendency	93
Figure 3.8: The European patent applications grant procedure	94
Figure 3.9: Patent option value	95
Figure 5.10: Typology of faculty views of academia-industry relationships	137
Figure 5.11: Queen's University Belfast pharmaceutical research cluster	139
Figure 5.12: Effect of legislative changes on university governance in Europe	142
Figure 5.13: Evolution of the technology business incubator model	145
Figure 5.14: Schematic of the Triple Helix model	148

## List of Tables

Table 1.1: The project checklist	44
Table 1.2: Financial contribution (from the sponsor) and external funding	45
Table 1.3: Checklist for participants' background information	45
Table 1.4: IPR of project results	46
Table 1.5: Confidentiality and academic publication	46
Table 1.6: Liability	47
Table 2.7: Academic versus industry management approach	64
Table 3.8: US legislation governing patenting and transfer of federally funded R&D	83